as on February 7, 2026 at 7:57 am IST
Day's Low
Day's High
11.62%
Downside
1.08%
Upside
52 Week's Low
52 Week's High
68.51%
Downside
15.00%
Upside
Check Insight Molecular Diagnostics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$86.7M
EPS (TTM)
-0.99
Dividend Yield
0.00%
PE Ratio (TTM)
0PEG Ratio
0Return On Equity TTM
-428.96%
Compare market cap, revenue, PE, and other key metrics of Insight Molecular Diagnostics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| NA | $86.7M | NA | NA | 0.00% | |
| BUY | $55.8B | 28.24% | 55.25 | 24.65% | |
| BUY | $235.4B | 10.21% | 36.24 | 15.02% | |
| BUY | $38.5B | 5.2% | 29.75 | 18.75% | |
| BUY | $169.5B | -8.06% | 48.81 | 14.44% |
Search interest for Insight Molecular Diagnostics Inc Stock has increased by 133% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:133% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 7 days, IMDX stock has moved up by 12.3%
Best in 1 Year
![]()
In the last 1 year, IMDX has outperformed top 5 stocks with highest market-cap in its industry
Against Peers
![]()
In the last 3 years, Idexx Laboratories, Inc. has given 27.0% return, outperforming this stock by 35.5%
Revenue Fall
![]()
Revenue is down for the last 3 quarters, 2.13M → 260.0K (in $), with an average decrease of 62.8% per quarter
Profit Down
![]()
Netprofit is down for the last 3 quarters, -6.67M → -10.85M (in $), with an average decrease of 28.7% per quarter
| Organisation | Insight Molecular Diagnostics Inc |
| Headquarters | 2 International Plaza Dr., Nashville, TN, United States, 37217 |
| CEO | Mr. Joshua Riggs |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Mr. Yuh-Min Chiang Ph.D. | Chief Technology Officer |
Mr. Peter Hong | VP, General Counsel & Secretary |
Dr. Paul R. Billings FACP, M.D., Ph.D. | Consulting Chief Medical Officer |
Dr. Michael D. West Ph.D. | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. |
Mr. Joshua Riggs | President, CEO & Director |
Ms. Andrea Susan James | Chief Financial Officer |
Mr. James Liu | VP of Accounting, Treasurer, Controller & Principal Accounting Officer |
Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
Ms. Sandra O'Donald | Senior Vice President of Business Operations |
Ms. Gabrielle Woody | Sr. Executive Assistant |
Insight Molecular Diagnostics Inc share price today is $7.4 as on at the close of the market. Insight Molecular Diagnostics Inc share today touched a day high of $7.48 and a low of $6.54.
Insight Molecular Diagnostics Inc share touched a 52 week high of $8.51 on and a 52 week low of $2.33 on . Insight Molecular Diagnostics Inc stock price today i.e. is closed at $7.4,which is 13.04% down from its 52 week high and 217.60% up from its 52 week low.
Insight Molecular Diagnostics Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Insight Molecular Diagnostics Inc (IMDX) shares with as little as ₹90.555 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹905.55 in Insight Molecular Diagnostics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Insight Molecular Diagnostics Inc share’s latest price of $7.4 as on February 7, 2026 at 2:27 am IST, you will get 1.3514 shares of Insight Molecular Diagnostics Inc. Learn more about
fractional shares .